Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 1.841 FI de cinco anos: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2015013843
pages 203-207

Dual Protective and Cytotoxic Benefits of Mesenchymal Stem Cell Therapy in Combination with Chemotherapy/Radiotherapy for Cancer Patients

Fatemeh Hendijani
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
Shaghayegh Haghjooy Javanmard
Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

RESUMO

Cancer is a major health problem in the world, and scientists seek innovative treatment strategies with higher efficacy and lower toxicity than the existing therapeutic agents. In this way, stem cell researchers try to reveal new pathways that will eventually benefit patients. Stem cell research has proven that mesenchymal stem cells (MSCs) possess anticancer activities, and their protein-rich secretome showed similar effects. MSCs also secrete cytokines that play an active role in healing and regeneration processes. Because of their known plasticity, MSCs display a variety of characteristics and functions in different environments, depending on their interactions with various cell types and tissues. Therefore, we hypothesize that MSC therapy in combination with anticancer medicines can potentiate cytotoxic effects on cancer cells. In addition, because of their regenerative capacity, MSCs can protect normal tissues from adverse cytotoxic drug reactions. They may also help rescue injured tissues from these toxic damages or systemic pathological events that occur during cancer treatment. MSC therapy may double the beneficial effects on cancer and normal cells. As our knowledge of systems biology and biotechnological methodology is progressing, this idea can move forward as a treatment option.


Articles with similar content:

Apoptosis as a Practical Target for Identifying Anticancer Agents of Marine Origin
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 1
Osamu Ohno, Kiyotake Suenaga, Toshiaki Teruya, Daisuke Uemura
Programming hMSCs into Potential Genetic Therapy in Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 4
Nedime Serakinci, Huseyin Cagsin
COMMENTARY. Regulation of Drug and Immune Resistance by YY1 in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
James A. McCubrey, Maria C. Mazzarino, Natale D'Alessandro
Human Mesenchymal Stem Cells in Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 1
Rasime Kalkan, Nedime Serakinci
Gain of Antitumor Functions and Induction of Differentiation in Cancer Stem Cells Contribute to Complete Cure and No Relapse
Critical Reviews™ in Oncogenesis, Vol.15, 2009, issue 1-2
Minal Garg